



October 09, 2018

**National Stock Exchange of India Limited,**  
Compliance Department,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (East), Mumbai - 400051,  
Maharashtra, India

**BSE Limited,**  
Compliance Department,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai - 400001,  
Maharashtra, India

**Sub: Press release**

**Ref: HealthCare Global Enterprises Limited (“the Company”) (NSE Scrip Code: HCG/ BSE Scrip Code: 539787)**

Dear Sir/Madam,

We wish to inform you that Strand Life Sciences Private Limited (“Strand Life Sciences”), an Associate of the Company, has signed an agreement to acquire India medical diagnostics business of Quest Diagnostics.

In this respect, the press release made by Strand Life Sciences is enclosed for your information.

Request you to take this on record.

Thanking you,

**For HealthCare Global Enterprises Limited**

**Sunu Manuel**  
**Company Secretary & Compliance Officer**

## **Strand Life Sciences Acquires India Diagnostics Business from Quest Diagnostics**

**8<sup>th</sup> October, BANGALORE, INDIA.** Strand Life Sciences, a Bangalore-based specialized research and diagnostics company today announced an agreement to acquire the India medical diagnostics business of Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services.

“This acquisition is an important addition to our network of 24 diagnostic labs across India, especially as we continue to expand our work in oncology, genomics, and precision medicine. It adds strong North India presence and marquee clientele that includes leading hospital chains, corporates and pharmaceutical clients to our portfolio, making us India’s leading specialized diagnostics company”, said Dr. Ramesh Hariharan, Chief Executive Officer, Strand Life Sciences.

Steve Rusckowski, Chairman, President and CEO, Quest Diagnostics, commented: “We have built a diagnostic laboratory in India with a reputation for quality over the past 10 years. As our business model has evolved, we believe Strand Life Sciences is well positioned to continue the important work of empowering the people of India to improve their health with diagnostic insights.”

The two companies will work together to manage the transition, and aim to close the sale by the end of first quarter of calendar year 2019. Terms of this transaction were not disclosed.

### **About Quest Diagnostics**

Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. [www.QuestDiagnostics.com](http://www.QuestDiagnostics.com).

### **About Strand Life Sciences**

Strand Life Sciences is a clinical research and diagnostics company that combines a long track record in bioinformatics with cutting-edge laboratory assays and a vast hospital partner network to drive newer generations of patient care. Strand’s customers include global instrument, diagnostic and pharmaceutical companies. Strand is also a pioneer of genomic testing in India. Strand’s diagnostics menu makes it India’s leading integrated specialized diagnostics company, covering oncology, genetics, fertility, women’s health, infectious diseases and general wellness. For more information, visit Strand’s website at <https://strandls.com/>